Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (PGNY) generates a steady flow of news as a global leader in women’s health and family building solutions listed on the Nasdaq Global Select Market. Company updates frequently focus on fertility and women’s health benefits, research on employee and member needs, and financial performance, giving investors and benefits professionals insight into how Progyny’s model is evolving.
News coverage commonly includes quarterly earnings results and financial guidance, which are also referenced in the company’s Form 8-K filings. These releases discuss revenue from fertility benefit services and pharmacy benefit services, member engagement trends, client additions, and key metrics such as assisted reproductive treatment cycles and utilization rates. Investors following PGNY news can see how changes in client count, covered lives, and engagement influence the company’s reported results and outlook.
Progyny also issues news about new programs and product expansions. For example, it has announced pregnancy, postpartum, and menopause programs for global employers that complement its existing global fertility and family building offering, along with details on features such as Global Care Advocates, knowledge centers, and country-specific navigator support. These announcements provide context on how Progyny is extending its reach across the women’s health continuum and into global markets.
Another important category of news involves research and thought leadership. Progyny has released studies on men’s fertility experiences and on gaps between employee expectations and employer offerings in women’s health benefits, conducted with Dynata. These stories highlight barriers such as stigma, cost, and benefit complexity, and they underscore the company’s focus on data-driven insights for employers.
Additional news items may cover conference participation, leadership recognition, and partnerships, such as appearances at healthcare conferences and recognition of the CEO as a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health. For anyone tracking PGNY, this news page offers a centralized view of operational, financial, and strategic developments over time.
Progyny (Nasdaq: PGNY) presented research at the ASRM Scientific Congress on October 17, 2020, focusing on factors influencing patient progression to infertility treatment. Analyzing 8,441 cases from 600 clinics with employer-sponsored coverage, key findings revealed that increased interactions with patient care advocates significantly boost treatment progression rates from 72% to 82%. Patients aged 35-38 were most likely to progress, while those with male infertility diagnoses showed lower progression rates. The study aims to enhance understanding of barriers patients face even when financial hurdles are addressed.
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced the participation of its CEO, David Schlanger, in a fireside chat at the BofA Global Healthcare Conference on September 17, 2020, at 11:45 A.M. ET. This event highlights the company's commitment to redefining fertility and family-building benefits. Progyny aims to empower patients through dedicated advocacy, access to specialists, and cost reduction for employers. The event will be audiocasted live and available for replay on Progyny's website.
Progyny (Nasdaq: PGNY) has appointed Mark Livingston as Chief Financial Officer, effective September 15, 2020. He brings over 30 years of experience, having previously served as CFO at Scripps Network Interactive and Emerson, Reid & Company. Livingston's promotion allows President Pete Anevski to focus more on business growth, as Progyny addresses significant market opportunities in fertility benefits management. The company aims to enhance patient outcomes and reduce costs for employers while expanding its leadership position in the market.
Progyny reported Q2 revenue of $64.6 million, marking a 15% increase from $56.2 million in 2019. Patient activity recovered faster than expected, with fertility treatment volumes improving as clinics reopened. For full-year 2020, revenue guidance is set between $323 million and $340 million, indicating growth of 41% to 48%. Q3 revenue is projected at $88 million to $95 million. However, the company noted a net loss of $1.8 million due to operational costs amid pandemic disruptions. Adjusted EBITDA was $3 million, reflecting resilience despite challenges.
Progyny (Nasdaq: PGNY) will announce its financial results for the quarter ending June 30, 2020, on August 5, 2020. The report will be released after market close, followed by a conference call at 4:45 PM ET.
Participants can access the call by dialing specific numbers for U.S. and international attendees. An audio replay will be available until August 11, 2020. Progyny, a leader in fertility benefits management, emphasizes a comprehensive approach that supports employers and patients alike.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced participation in the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020. CEO David Schlanger and President Pete Anevski will join a fireside chat at 4:40 P.M. Eastern Time. Progyny aims to redefine fertility benefits, offering solutions that include dedicated Patient Care Advocates and access to a network of specialists. Recognized as a CNBC 50 Disruptor and among the fastest-growing companies, Progyny continues to innovate in family building benefits.
Progyny, Inc. (Nasdaq: PGNY) reported a 72% increase in revenue for Q1 2020, achieving $81.0 million, up from $47.2 million in Q1 2019. This growth was driven by a 47% rise in fertility services revenue. The company also reported $12.1 million in operating cash flow and net income of $4.1 million, a 61% increase year-over-year. Despite disruptions due to COVID-19, management remains optimistic about recovery and expects a minimum of $45 million in revenue for Q2 2020. However, uncertainty still exists regarding the full resumption of services amid ongoing pandemic challenges.
Progyny, a leader in fertility benefits management, announced that CEO David Schlanger and President Pete Anevski will participate in a fireside chat at the BofA Securities 2020 Health Care Conference on May 14, 2020, at 3:00 PM ET. The event will be accessible via live audiocast and replay on Progyny's investor website. Progyny aims to redefine family building benefits, providing education and access to fertility specialists, while reducing healthcare costs. The company has earned multiple accolades, including recognition from CNBC and Financial Times.